A study looking at a new type of mammogram to see if it reduces the number of people needing to repeat screening tests (CIST)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Status:
Phase:
This study is collecting information from mammograms using a Philips Microdose SI mammogram machine. This is called spectral mammography.
Researchers want to see if they can reduce the number of people who might need a repeat mammogram or other tests because it is not clear if an abnormal area is cancer or not.
Women between the ages of 50 to 70 are routinely screened for breast cancer using mammograms. This is the best way to diagnose breast cancer early.
More about this trial
A mammogram is an X-ray of the breast. It is routinely used but there can be some problems using mammograms.
One problem is that sometimes it can be difficult to tell the difference between what might be breast cancer and what isn’t.
If a mammogram is not clear enough or shows any abnormal area, or 
, you may need to go back to have other tests done.
Spectral mammography is an advanced way to look at abnormal breast lesions. It could reduce the need to do other tests to rule out or confirm a diagnosis of cancer.
The aims of this study are to
- collect information obtained during routine mammograms and use spectral mammography to look at the breast lesions
- see if spectral mammography can reduce the number of
false positive results - see if spectral mammography can reduce the number and costs of further tests
Who can enter
The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you
You may be able to join this study if you are a woman going to the Cambridge Breast Unit or the Hereford and Worcester breast screening service and all of the following apply
- You are aged 35 years or over
- Your doctor has asked you to have a mammogram or you have been recalled from screening
- If you have at least 1 round or oval lesion in one or both breasts
Trial design
This is a pilot international study. In the UK the researchers need about 600 women who are having their mammogram at the Cambridge Breast Unit or the Hereford and Worcester breast screening service to take part.
Your mammogram will be done in the usual way. If necessary you will be referred for more tests such as an ultrasound scan and biopsy.
The images will be stored and looked at closely by the study team after all your tests results are available. Your details will be removed from the images so that no one will be able to identify you.
The study team will particularly look to see if spectral mammography is better at showing what might be cancer and what isn’t. And reduce the number of women having to have a repeat mammogram or other tests.
Hospital visits
You will not need to attend any extra visits as part of this study. Your mammogram will be done as part of your normal care.
Side effects
There are no side effects associated with taking part in this study.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Matthew Wallis
Supported by
Cambridge University Hospitals NHS Foundation Trust
NIHR Clinical Research Network: Cancer
Phillips Digital Mammography Sweden AB
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
